SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Focused Visit (Care-plan review) — Mahalia Jackson

PatientMahalia Jackson
Date of birth1973-10-26
IdentifiersMRN HR-ML035-SYN; SSN (made up) 000-35-4692
Document date2026-08-24
AuthorBeatrice Fontenot, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Six-month review with the repeat FDG-PET. [S]

History of Present Illness

Ms. Jackson returns after about five and a half months of treatment. The repeat FDG-PET a week ago shows no remaining inflammation in the heart and much less in the lymph nodes, and the echocardiogram the same day shows an ejection fraction of 54 percent. She has taken prednisone 10 mg for three weeks and methotrexate 20 mg weekly. The laryngitis in June settled within ten days, and she has sung two concerts a week since late May without trouble. Her monthly methotrexate blood tests have been normal. The remote device checks show no ventricular tachycardia since March. She sleeps better on the lower dose and her appetite has settled. She would like to plan an autumn tour. She has had no thoughts of self-harm. [S]

ElementDetail
FDG-PET and echocardiogramNo myocardial uptake; nodes smaller with low uptake; ejection fraction 54 percent from 47
TreatmentPrednisone 10 mg; methotrexate 20 mg weekly
DeviceNo ventricular tachycardia since March; no shocks
WorkTwo concerts a week since late May; autumn tour proposed
LaryngitisResolved within ten days

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight 93.0 kg; no fever
RespiratoryNegativeBreathless only on hills; no cough
CardiovascularNegativeNo palpitations, shocks or fainting
Ears, nose, mouth, and throatNegativeVoice back to normal; no mouth sores
EyesNegativeNo redness or blurred vision
PsychiatricNegativeSleeping better; PHQ-9 4; no thoughts of self-harm

6 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Prednisone 20 mg oral tablet, two tablets (40 mg) by mouth each morning40 mg each morningOral route2026-03-09 to 2026-05-11completedS
Prednisone 10 mg oral tablet, three tablets (30 mg) by mouth each morning for four weeks30 mg each morning for four weeksOral route2026-05-11 to 2026-06-08completedS
Prednisone 20 mg oral tablet, one tablet (20 mg) by mouth each morning for four weeks20 mg each morning for four weeksOral route2026-06-08 to 2026-07-06completedS
Prednisone 5 mg oral tablet, three tablets (15 mg) by mouth each morning for four weeks15 mg each morning for four weeksOral route2026-07-06 to 2026-08-03completedS
Prednisone 10 mg oral tablet, one tablet (10 mg) by mouth each morning10 mg each morningOral route2026-08-03 to 2026-09-21completedS
Methotrexate 2.5 mg oral tablet, six tablets (15 mg) by mouth once a week on Sundays15 mg once weeklyOral route2026-03-09 to 2026-05-11completedS
Methotrexate 2.5 mg oral tablet, eight tablets (20 mg) by mouth once a week on Sundays20 mg once weeklyOral route2026-05-11activeS
Folic acid 1 mg oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-03-09activeS
Atovaquone 750 mg/5 mL oral suspension, 1500 mg (10 mL) by mouth once daily with food1500 mg once daily with foodOral route2026-03-09 to 2026-07-06completedS
Alendronate 70 mg oral tablet, one tablet by mouth once weekly on rising, with a full glass of water, staying upright for 30 minutesOne tablet once weeklyOral route2026-03-16activeS
Metoprolol succinate 25 mg extended-release oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-03-09activeS
Cholecalciferol (vitamin D3) 25 mcg (1000 units) oral tablet, one tablet by mouth dailyOne tablet dailyOral route2026-05-11activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-08-24Body height170cmS
2026-08-24Body weight93kgS
2026-08-24Body mass index (BMI) [Ratio]32.2kg/m2S
2026-08-24Systolic blood pressure130mm[Hg]S
2026-08-24Diastolic blood pressure82mm[Hg]S
2026-08-24Heart rate64/minS
2026-08-24Respiratory rate16/minS
2026-08-24Body temperature36.7CelS
2026-08-24Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-08-24Hemoglobin [Mass/volume] in Blood13g/dL12-15.5 g/dLNormalS
2026-08-24Leukocytes [#/volume] in Blood by Automated count8.110*3/uL4-11 10*3/uLNormalS
2026-08-24Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
2026-08-24Platelets [#/volume] in Blood by Automated count24810*3/uL150-400 10*3/uLNormalS
2026-08-24Creatinine [Mass/volume] in Serum or Plasma0.9mg/dL0.59-1.04 mg/dLNormalS
2026-08-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M77mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2026-08-24Glucose [Mass/volume] in Serum or Plasma108mg/dL70-99 mg/dLHighS
2026-08-24Calcium [Mass/volume] in Serum or Plasma9.5mg/dL8.6-10.3 mg/dLNormalS
2026-08-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma29U/L7-35 U/LNormalS
2026-08-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma27U/L8-35 U/LNormalS
2026-08-24Alkaline phosphatase [Enzymatic activity/volume] in Serum or Plasma90U/L35-104 U/LNormalS
2026-08-24Albumin [Mass/volume] in Serum or Plasma4.1g/dL3.5-5 g/dLNormalS
2026-08-24Hemoglobin A1c/Hemoglobin.total in Blood6.2%Below 5.7% is normal; 5.7 to 6.4% prediabetes; 6.5% or more diabetesHighS
2026-08-2425-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mL30-100 ng/mLNormalS
2026-08-24Natriuretic peptide.B prohormone N-Terminal [Mass/volume] in Serum or Plasma96pg/mL<=125 pg/mLNormalS
2026-08-24FVC measured/predicted90%>=80%NormalS
2026-08-24FEV1 measured/predicted89%>=80%NormalS
2026-08-24FEV1/FVC79%>=70%NormalS
2026-08-24Diffusion capacity.carbon monoxide/Predicted76%>=80%LowS
2026-08-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S

Physical Exam

Vital signs recorded on 2026-08-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; weight 93.0 kg; blood pressure 130/82, pulse 64 and regular
RespiratoryClear to auscultation
CardiovascularRegular rhythm; no murmur; device pocket normal
MouthNo thrush or ulcers; voice clear
SkinNo rash, plaques or bruising
PsychiatricLively; planning her season

Problems

ProblemClinical statusVerificationCodeProvenance
Breathlessness on exertion and a dry cough for three months, worse on tour, with tiredness and chest tightness; she can no longer hold long phrases; bilateral hilar lymph node enlargement on today's chest radiograph; granulomas were reported at an abdominal operation twelve years ago, with no pathology report available: sarcoidosis must be confirmed by tissue and other causes excludedresolvedconfirmed R06.09S — Synthetic presenting problem anchored to the documented breathlessness during performances and the 1952 granulomas. Superseded by the tissue diagnosis at the consultation.
Palpitations with two spells of light-headedness while singing; ECG today: sinus rhythm with first-degree atrioventricular block (PR 240 ms) and frequent ventricular ectopic beats: cardiac involvement must be looked forresolvedconfirmed R00.2S — Synthetic finding; superseded when cardiac sarcoidosis was diagnosed.
Hypercalcemia: calcium 10.8 mg/dL with a high 1,25-dihydroxyvitamin D and a low 25-hydroxyvitamin D, while taking an over-the-counter calcium and vitamin D supplement; creatinine slightly raisedresolvedconfirmed E83.52S — Synthetic finding; resolved on treatment.
Pulmonary sarcoidosis with hilar and mediastinal lymph node involvement (Scadding stage II), confirmed by non-necrotizing granulomas on EBUS-guided lymph node aspiration with negative stains and cultures; mild restriction and reduced diffusing capacity; synthetic modern detail linked to her documented sarcoidosisactiveconfirmed D86.2S — Synthetic histology, stage and lung function; her biographer reports a diagnosis of sarcoidosis after granulomas were found at an operation (D, probable).
Acute viral laryngitis: three days of hoarseness, a sore throat and a mild dry cough after a cold, without fever, on prednisone 20 mg and methotrexate; rapid influenza and COVID-19 tests negative; no thrush; resolvedresolvedconfirmed J04.0S — Synthetic acute infection; not a historical claim.
Cardiac sarcoidosis: first-degree atrioventricular block, ventricular ectopy (6 percent of beats) with nonsustained ventricular tachycardia, left ventricular ejection fraction 47 percent, patchy late gadolinium enhancement of the basal septum and inferolateral wall, and matching focal FDG uptake on PET; synthetic modern detail linked to the documented private account that sarcoidosis was in her heartactiveconfirmed D86.85S — Synthetic cardiac findings; the account that her doctors told her sarcoidosis was in her heart rests on her biographer (D, probable), and the interpretation of her later heart disease is R.
Long-term systemic glucocorticoid treatment for sarcoidosis, with bone, glucose, blood pressure, infection and eye risks to manageactiveconfirmed Z79.52S — Synthetic treatment status.
Dual-chamber implantable cardioverter-defibrillator, placed after sustained monomorphic ventricular tachycardia was induced at electrophysiology study; remote monitoringactiveconfirmed Z95.810S — Synthetic device status after the synthetic implant.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ImagingCardiac FDG-PETThree to six months into treatment, and after major dose changesUp to dateA week ago: no myocardial uptake; nodes smaller with low uptake
ImagingEchocardiogramWith the repeat PET, and for symptomsUp to dateA week ago: ejection fraction 54 percent
ImagingSpirometry and diffusing capacity (FVC, FEV1, FEV1/FVC, DLCO)At diagnosis, three months after starting treatment, then every three to six months while treatment changesCompleted todayFVC 90 percent, FEV1 89 percent, FEV1/FVC 79 percent, DLCO 76 percent of predicted
LaboratoryMethotrexate safety: blood count, liver tests and creatinineBefore starting; every two to four weeks for the first three months; then every eight to twelve weeksCompleted todayHemoglobin 13.0 g/dL, white cells 8.1, lymphocytes 1.4, platelets 248; ALT 29, AST 27, alkaline phosphatase 90 U/L, albumin 4.1 g/dL; creatinine 0.90 mg/dL, eGFR 77; the monthly tests since May were normal; now every eight to twelve weeks
LaboratorySerum calciumAt diagnosis, then at each treatment visit while it was raised or vitamin D is givenCompleted today9.5 mg/dL on cholecalciferol
Laboratory25-hydroxyvitamin DAfter replacement startsCompleted today34 ng/mL
LaboratoryGlucose and A1c on glucocorticoidsAt each visit; A1c every three monthsCompleted todayGlucose 108 mg/dL; A1c 6.2%
LaboratoryNT-proBNPAt each cardiac reviewCompleted today96 pg/mL, normal
ExaminationDefibrillator check (remote and in clinic)Remote transmissions monthly and with any symptom; clinic check every three to six monthsCompleted todayRemote transmissions monthly: no ventricular tachycardia since March; clinic check booked this month
ExaminationEye examinationYearly with sarcoidosis and on glucocorticoidsUp to dateNormal in March; next due in March
ImagingBone density (DXA)Every one to three years on glucocorticoidsUp to dateMarch; repeat in two years
Medication safetyPneumocystis prophylaxisWhile prednisone is 20 mg or more with a second immunosuppressantNot indicatedStopped in July when prednisone fell below 20 mg
Medication safetyVaccination on immunosuppressionPer scheduleCompleted todayRecombinant zoster dose 2 given today; influenza and COVID-19 due in the autumn
SurveyDepression screen (PHQ-9)At diagnosis and at each phase of treatmentCompleted todayPHQ-9 4
Self-managementPerforming and travel planAt each visitCompleted todayAutumn tour in the United States approved with rest days and the same medicine and device plan; a tour abroad next spring to be decided after the next review

Goal progress:

Immunizations given today: Recombinant zoster vaccine, dose 2 of 2 [S]

Guideline basis: Crouser ED, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;201(8):e26-e51 (PMID 32293205) (2020); Baughman RP, et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur Respir J 2021;58(6):2004079 (PMID 34140301) (2021); Birnie DH, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014;11(7):1305-1323 (PMID 24819193) (2014); Cheng RK, et al. Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association. Circulation 2024;149(21):e1197-e1216 (PMID 38634276) (2024); Humphrey MB, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis Rheumatol 2023;75(12):2088-2102 (PMID 37845798) (2022); Singh JA, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012;64(5):625-639 (PMID 22473917) (methotrexate laboratory monitoring) (2012); Adult Immunization Schedule by Medical Condition and Other Indication (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Clinic device check this month. Methotrexate blood tests every eight to twelve weeks. Preventive visit in about six weeks with influenza and COVID-19 vaccines. Pulmonology review in three months. Next scheduled visit 2026-10-05: periodic adult preventive visit. [S]